Leukemia, Promyelocytic, Acute: all 110 studies
Page 1 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory PracticeNot yet recruitingNCT07867704Not applicable
- Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsNot yet recruitingNCT07597941Phase 2/3
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaRecruitingNCT07504458Phase 3
- A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)Not yet recruitingNCT07296445Phase 3
- Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic LeukemiaRecruitingNCT06982274Phase 2
- Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsEnrolling by invitationNCT06544109Phase 2/3
- Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic LeukemiaRecruitingNCT05881265Phase 2
- Optimum Induction Therapy of Low-risk APLRecruitingNCT05832320Not applicable
- Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APLRecruitingNCT05497310Phase 1/2
- RWE of 1st Line Treatment With ATO/ATRA for Adult APLRecruitingNCT04897490
- Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaRecruitingNCT04793919Phase 2
- Frontline Oral Arsenic Trioxide for APLRecruitingNCT04687176Phase 2
- The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) ProjectRecruitingNCT04251754
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 1
- PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT02390635Phase 1
- National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML IntergroupRecruitingNCT02192619
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingNCT01409161Phase 2
- Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic LeukemiaActive, not recruitingNCT03253848Not applicableResults posted
- Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in RemissionTerminatedNCT01465386Phase 2Results posted
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
- Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission TherapyCompletedNCT01404949Phase 2Results posted
- Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01253070Phase 2Results posted
- Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)CompletedNCT01191541Phase 4Results posted
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic LeukemiaCompletedNCT00866918Phase 3Results posted
- Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00602225Phase 1/2Results posted
- Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaCompletedNCT00551460Phase 2Results posted
- Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic LeukemiaTerminatedNCT00528450Phase 2Results posted
- S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00492856Phase 3Results posted
- All-trans Retinoic Acid, and Arsenic +/- IdarubicinCompletedNCT00413166Phase 2Results posted
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
- Vorinostat in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00305773Phase 2Results posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only AssessmentCompletedNCT07203885Not applicable
- Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaActive, not recruitingNCT07187505Not applicable
- Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic LeukemiaCompletedNCT06882031Phase 1
- A Study for Oral SY-2101 for Participants With Acute Promyelocytic LeukemiaSuspendedNCT04996030Phase 1
- Results From a Mexican Acute Promyelocytic Leukemia.CompletedNCT04562818
- Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic LeukemiaStatus unknownNCT04446806Phase 4
- Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APLStatus unknownNCT04175587Phase 3
- Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITDTerminatedNCT03989713Phase 2
- Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic LeukemiaStatus unknownNCT03751917
- Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic LeukaemiaStatus unknownNCT03624270Phase 2
- Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard ChemotherapyStatus unknownNCT03096496
- Role of Microparticles in the Coagulopathy of Acute Promyelocytic LeukemiaStatus unknownNCT02991066
- French Registry of First-line Treatment of Acute Promyelocytic LeukemiaCompletedNCT02938858
- Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)Status unknownNCT02899169Phase 3
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedNCT02688140Phase 3
- Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a DatabaseTerminatedNCT02309333
- A Study for Improving the Outcome of Childhood Acute Promyeloid LeukemiaCompletedNCT02200978Phase 4
- Red Cell Transfusion Goals in Patients With Acute LeukemiasCompletedNCT02086773Phase 1
- Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APLStatus unknownNCT01987297Phase 4
- Proteasome Inhibition in Acute Promyelocytic LeukemiaStatus unknownNCT01950611Phase 2
- Long-Term Quality of Life in Patients With Acute Promyelocytic LeukemiaCompletedNCT01910623
- A Safety Study of SGN-CD33A in AML PatientsCompletedNCT01902329Phase 1
- Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaApproved for marketingNCT01869803
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaWithdrawnNCT01548911Phase 2
- Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With ChemotherapyCompletedNCT01472107
- Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfilerTerminatedNCT01463410
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Biomarkers in Tissue Samples From Patients With Acute Promyelocytic LeukemiaCompletedNCT01232855
- Treatment Study for Children and Adolescents With Acute Promyelocitic LeukemiaStatus unknownNCT01226303Phase 3
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic LeukemiaCompletedNCT01146223
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
- AIDA 2000 GuidelinesStatus unknownNCT01064570Phase 2
- Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01031368Phase 1
- Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaCompletedNCT01005277
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic LeukemiaTerminatedNCT00985530Phase 1
- Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
- ASCT for Relapsed APL After Molecular RemissionTerminatedNCT00907582Phase 2
- Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00875745Phase 1
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic LeukemiaStatus unknownNCT00675870Phase 2
- New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic LeukemiaWithdrawnNCT00670150Phase 2
- APL93: Timing of CxT and Role of MaintenanceCompletedNCT00599937Phase 3
- A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)CompletedNCT00591526Phase 3
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APLCompletedNCT00520208Phase 2
- Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic LeukemiaStatus unknownNCT00517712Phase 2/3
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)CompletedNCT00504764Phase 4
- Phase III Trial in Acute Promyelocytic Leukemia PatientsCompletedNCT00482833Phase 3
- Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)CompletedNCT00465933Phase 4
- Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)CompletedNCT00408278Phase 4
- Acute Promyelocytic Leukemia 2006 (APL)Status unknownNCT00378365Phase 3
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- Combination Chemotherapy in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00276601Phase 2
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
- Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With ArsenicStatus unknownNCT00196768Phase 4
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)TerminatedNCT00185523
- AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic LeukemiaStatus unknownNCT00180128Phase 4
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
- Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
- Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDSCompletedNCT00053287Phase 2